

Contents

General Preface to Series	v
Preface to Second Edition	vi
Preface to First Edition	vii
1 Introduction	1
2 Tumour-specific Antigens in Experimental Animals	4
Historical introduction	4
Chemically-induced tumours	6
Virus-induced tumours	6
Plastic film-induced tumours	7
Ultraviolet light-induced tumours	7
Spontaneous tumours	7
Other methods for the detection of tumour antigens	8
Differentiation antigens	10
The thymus-leukaemia antigen (TL)	11
Gix antigen	11
Embryonic antigens	11
3 Immunological Mechanisms in Surveillance against Oncogenesis	14
There is no surveillance	14
Immunological surveillance and allograft rejection	16
Immune deficiency states	18
Iatrogenic immunosuppression	18
Immunological responsiveness in cancer patients	19
Carcinogenesis in animals	19
Surveillance and macrophages	21
'Natural immunity' and surveillance	23
Counter surveillance	27
Conclusion	30
4 Host Resistance and the Immune Response	32
Experimental immunosuppression	33
Carcinogenetic latent period	33
Concomitant immunity	33
Clinical evidence for immunological reactions to human tumours	35
Spontaneous regression	35
Prolonged survival of patients with tumours	35
Post-mortem prevalence	36
Regression of metastases after excision of the primary tumour	36
Waxing and waning of tumour deposits	36
Responses to chemotherapy	37
Histological evidence	38

5 The Antigenicity of Human Tumours	40
Humoral responses to tumours	42
Burkitt's lymphoma	42
Malignant melanoma	43
Sarcomas	44
Autoantibodies to normal tissue components	44
Cell-mediated responses to human tumours	46
Delayed cutaneous hypersensitivity	46
Stimulation of lymphocyte DNA synthesis	46
Production of migration inhibitory factor (MIF)	46
Lymphocyte cytotoxicity	47
Leukocyte adherence inhibition (LAI) test	49
Xenogeneic antisera in the detection of tumour-specific antigens	50
 6 Effector Mechanisms in Tumour Immunity	 53
Specific humoral mechanisms	54
Complement-dependent cytotoxic antibody	55
Antibody and growth inhibition	56
Inhibition of tumour cell motility by antibody	56
Reaginic antibody	57
Cell-dependent antibody (or antibody-dependent cellular cytotoxicity)	57
Natural antibodies	59
Lymphokines	59
Cell-mediated immunity	60
Immunoblasts	62
Thymus-derived lymphocytes (T cells)	64
Bone-marrow-derived lymphocytes (B cells)	66
Natural killer (NK) cells	67
Macrophages and monocytes	67
Other possible effector cells	70
 7 Immunological Escape of Tumours	 73
Immunological unresponsiveness	74
Specific immunological tolerance	74
Non-specific immunodeficiency	75
Immunoselection	76
'Sneaking through'	76
Cell kinetics	77
Phenotype modification of tumour cell antigens	77
Antigenic modulation	77
Shedding of antigens	77
Immunological Sanctuaries	78
Abrogation of immune reactions by humoral factors	78
Immunological enhancement and blocking antibody	79
Circulating antigen, immune complexes, blocking and inhibition	81
Suppressor cells	85
Non-specific suppressor cells	85
Specific suppressor cells	86
Conclusion	86

8 Immunotherapy of Human Cancer: prospect and retrospect	88
Rationale	88
Specific active immunotherapy	91
Specific passive immunotherapy	95
Non-specific active immunotherapy	97
Adoptive immunotherapy	98
Other approaches to immunotherapy	98
The present status of immunotherapy	100
Tumour vaccines	103
Non-specific immunostimulation	103
Harmful effects of immunotherapy	105
Other potential dangers of immunotherapy	106
Immunotherapy as part of a combined treatment	107
Long-term prospects	110
Immunoprophylaxis	111
Conclusion	112
 9 Immunodiagnosis	116
Tumour marker substances	117
Enzymes	117
Hormones	118
Carcinoembryonic antigen	118
Fetoproteins	119
Other tumour cell products	120
Host responses in immunodiagnosis	121
Circulating anti-tumour antibodies	122
Cell-mediated immunity	122
Blocking and inhibiting serum factors	122
Macrophage electrophoretic mobility (MEM) test	123
SCM test	123
LAI test	124
 Index	127